About the Lab
The Abraham Laboratory has a primary aim of advancing curative therapies for sickle cell disease such as allogeneic hematopoietic stem cell transplantation and autologous hematopoietic stem cell gene therapy approaches. The lab focuses on the immunobiology of hematopoietic cell engraftment, virus-specific immunity restoration following transplantation, and identifying the best hematopoietic stem cell source for gene modification to treat patients during early childhood prior to the development of irreversible complications of sickle cell disease.
Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipientsAbraham AA, John TD, Keller MD, Cruz CRN, Salem B, Roesch L, Liu H, Hoq F, Grilley BJ, Gee AP, Dave H, Jacobsohn DA, Krance RA, Shpall EJ, Martinez CA, Hanley PJ, Bollard CM PMCID: PMC6650740 Blood Adv. 3(14):2057-2068 July (2019)
Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell diseaseAbraham AA, Lang H, Meier ER, Nickel RS, Dean M, Lawal N, Speller-Brown B, Wang Y, Kean L, Bollard CM PMCID: PMC6707525 Pediatr Blood Cancer 66(5):e27601 May (2019)